A study to evaluate surovatamig combined with R-CHOP in participants of 18 to < 80 years of age with previously untreated large B-cell lymphoma with IPI score 2 to 5 - Soundtrack D3

Study identifier:D7403C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A Phase III Study to Evaluate the Efficacy of Surovatamig Combined with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Previously Untreated Large B-cell Lymphoma (Soundtrack D3)

Medical condition

Large B-cell lymphoma

Phase

Phase 3

Healthy volunteers

Study drug

Surovatamig, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Polatuzumab vedotin

Sex

All

Estimated Enrollment

1200

Study type

Interventional

Age

18 Years - 79 Years

Date

Study Start Date: 22 Dec 2026

Estimated Primary Completion Date: 02 Sept 2030

Estimated Study Completion Date: 01 Sept 2032

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2026 by AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: Surovatamig and R-CHOP Participants will receive surovatamig in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy according to standard of care (SoC).	Drug: Surovatamig Fully human bispecific monoclonal immunoglobulins (Ig) G4 antibody Other Name: AZD0486 Drug: Rituximab Rituximab will be administered to participants as per SoC. Drug: Cyclophosphamide Cyclophosphamide will be administered to participants as per SoC. Drug: Doxorubicin Doxorubicin will be administered to participants as per SoC. Drug: Vincristine Vincristine will be administered to participants as per SoC. Drug: Prednisone Prednisone (or equivalent) will be administered to participants as per SoC.
Active Comparator: R-CHOP or Pola-R-CHP Participants will receive either R-CHOP or Pola-R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone [or equivalent]) and polatuzumab vedotin) according to SoC.	Drug: Rituximab Rituximab will be administered to participants as per SoC. Drug: Cyclophosphamide Cyclophosphamide will be administered to participants as per SoC. Drug: Doxorubicin Doxorubicin will be administered to participants as per SoC. Drug: Vincristine Vincristine will be administered to participants as per SoC. Drug: Prednisone Prednisone (or equivalent) will be administered to participants as per SoC. Drug: Polatuzumab vedotin Polatuzumab vedotin will be administered to participants as per SoC.

Arms

Assigned Interventions

Experimental: Surovatamig and R-CHOP
Participants will receive surovatamig in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy according to standard of care (SoC).

Drug: Surovatamig
Fully human bispecific monoclonal immunoglobulins (Ig) G4 antibody

Other Name: AZD0486

Drug: Rituximab
Rituximab will be administered to participants as per SoC.

Drug: Cyclophosphamide
Cyclophosphamide will be administered to participants as per SoC.

Drug: Doxorubicin
Doxorubicin will be administered to participants as per SoC.

Drug: Vincristine
Vincristine will be administered to participants as per SoC.

Drug: Prednisone
Prednisone (or equivalent) will be administered to participants as per SoC.

Active Comparator: R-CHOP or Pola-R-CHP
Participants will receive either R-CHOP or Pola-R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone [or equivalent]) and polatuzumab vedotin) according to SoC.